Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207308 | 0.92 | KMO (0.39) | RIPK1MAPK14LMNAPOLBCACNA1B | |
| SCHEMBL19207261 | 0.92 | KDM5A (0.38) | CSNK1ERIPK1LMNACNR1POLB | |
| SCHEMBL19207305 | 0.89 | CNR1 (0.41) | RIPK1CNR1POLB | |
| SCHEMBL19207296 | 0.89 | CNR2 (0.41) | CNR1POLB | |
| SCHEMBL19641893 | 0.88 | WDR5 (0.35) | SRCRIPK1MAPK13MAPK12MAPK11 | |
| SCHEMBL29727663 | 0.88 | WDR5 (0.35) | SRCRIPK1MAPK13MAPK12MAPK11 | |
| SCHEMBL19207284 | 0.88 | MAPT (0.40) | RIPK1LMNA | |
| SCHEMBL19207339 | 0.86 | CTRC (0.39) | RIPK1LMNACACNA1B | |
| SCHEMBL19207297 | 0.86 | WDR5 (0.41) | CSNK1DCSNK1ESRCRIPK1MAPK13 | |
| SCHEMBL19207304 | 0.85 | CNR1 (0.45) | RIPK1LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473462-B | Pyrazole-pyridine derivatives as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | claimed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-29 | — | — | US | claimed |
| CN-108473462-B | Pyrazole-pyridine derivatives as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3411365-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-29 | — | — | US | disclosed |
| WO-2017133990-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017133990-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457663-B2 | Pyrazol-pyridine derivatives | MC3R, MC2R, DRD3 | CSNK1D 349/4885CSNK1E 802/4885SRC 1426/4885 |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | MC3R, MC2R, DRD3 | CSNK1D 349/4885CSNK1E 802/4885SRC 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.